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a  b  s  t  r  a  c  t
Although  the use of drug-eluting  stents  (DES)  has  reduced  the  rate  of  restenosis,  some  problems  remain
regarding  the  usefulness  of  DES  in  small  coronary  arteries  in addition  to late  thrombosis  and  a  longer
duration  of  dual-antiplatelet  therapy.  We  considered  335  patients  with  698  lesions  who  underwent  DES
or bare-metal  stent  (BMS)  implantation,  and  randomly  selected  172  DES  and  124  BMS  lesions  that  had
undergone  a  complete  data  analysis  and evaluation.  Patients  had  a history  of stable  angina  with  at  least  1
lesion  with  50%  diameter  stenosis  in a vessel  and  with  a successfully  minimum  stent implantation  (stent
diameter  =  2.5  mm).  The  baseline  characteristics  including  the  clinical  presentation  and  cardiovascular
risk  factors  were  similar  between  the  DES  and  BMS  groups,  except  for the  percentage  of dyslipidemia  (DL).
Pre-procedure  reference  vessel  diameter  (RVD  pre) in  the  DES  group  was signiﬁcantly  smaller  than  that
in the BMS  group  (p < 0.01),  and  stent  length  in  the DES  group  was  signiﬁcantly  longer  (p <  0.01).  There
was  no  signiﬁcant  difference  in  the  cumulative  incidence  of major  adverse  cardiac  events including  the
target  lesion  revascularization  rate,  whereas  in-stent  restenosis  (ISR)  in  the  DES  group  was  signiﬁcantly
lower  than  that in the BMS  group.  In  a multivariate  analysis  of  ISR,  diabetes  mellitus,  prior percutaneous
coronary  intervention,  and  DES  use  in  clinical  background  were  identiﬁed  as  independent  predictors  of
ISR.  In addition,  RVD pre,  stent  length,  and  DES  use  in angiographical  background  were  also  identiﬁed.  In
conclusion,  DES  use is an independent  predictor  of  ISR,  although  the DES  group  included  more  severely
rteri
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Drug-eluting stent (DES) implantation reduces restenosis after
ercutaneous coronary intervention (PCI) compared to bare-metal
tent (BMS) implantation [1].  However, there are no differences in
he rates of death and myocardial infarction (MI) between DES and
MS  implantation [1].  Moreover, DES is still associated with late-
tent thrombosis and prolonged dual-antiplatelet therapy [2,3]. The
actors that are related to late-stent thrombosis, as summarized by
he science advisory committees of the American College of Cardiol-
gy/American Heart Association/Society of Cardiovascular Angiog-
aphy and Interventions/American College of Surgeons/American
ental Associations, include stenting in small vessels, multi-
le lesions, long stents, overlapping stents, bifurcated lesions,
rior brachytherapy, low-ejection fraction, diabetes mellitus (DM),
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renal failure, acute coronary syndrome, and premature discon-
tinuation of anti-platelet therapy [4].  There have been several
reports regarding the clinical outcome after DES implantation. Lit-
tle is known about the patient background and clinical results for
DES implantation in small coronary arteries, although the rates of
restenosis and target lesion revascularization (TLR) are higher in
small coronary arteries than in larger coronary arteries after percu-
taneous coronary intervention (PCI) [5]. In addition, although the
amount of neointimal hyperplasia is largely independent of ves-
sel size, PCI in small coronary arteries may  be associated with an
increased risk of TLR [6].  Therefore, the purpose of this study was to
evaluate the baseline patient and angiographic characteristics and
clinical outcomes with DES or BMS  implantation in small coronary
arteries from the Fukuoka University Registry (FU-Registry).
MethodsSubjects and study design
This study was conducted at Fukuoka University Hospital,
Fukuoka University Chikushi Hospital, and Fukuoka Hakujuji


























































more severe QCA data than the BMS  group. Lesion length in the DES
group was signiﬁcantly longer, and reference vessel diameter (RVD)
and MLD  were smaller than those in the BMS  group.
Table 1
Patient characteristics at baseline.
DES (n = 132) BMS (n = 100) p-Value, DES
vs. BMS
Age (years) 65.2 ± 9.7 65.7 ± 10.9 0.23
BMI  (%) 24.0 ± 3.5 24.0 ± 3.3 0.89
Male (%) 80 75 0.30
LVEF  (%) 61.6 ± 12.2 58.8 ± 12.4 0.20
DM  (%) 60 49 0.06
HT  (%) 77 70 0.16
DL  (%) 81 70 0.03
Current smoking (%) 28 30 0.15
Prior MI  (%) 31 34 0.50
Prior PCI (%) 48 38 0.06
Prior CABG (%) 6 8 0.50
Medications (%)
ACE-I 7 7 0.88
ARB 68 67 0.82
CCB  49 51 0.60
-Blocker 11 5 0.07
Diuretics 21 22 0.79
Nitrate 30 29 0.88
Statin 80 74 0.97
Nicorandil 33 36 0.60
SU  15 10 0.15
-GI  12 7 0.16
Insulin 26 19 0.21
DES, drug-eluting stent; BMS, bare metal stent; BMI, body mass index; LVEF, left
ventricular ejection fraction; DM,  diabetes mellitus; HT, hypertension; DL, dyslipid-
emia; MI,  myocardial infarction; PCI, percutaneous coronary intervention; CABG,
coronary artery bypass graft; ACE-I, angiotensin-converting enzyme inhibitor; ARB,
angiotensin II receptor blocker; CCB, calcium channel blocker; SU, sulfonylurea;
-GI, -glycosidase inhibitor.
Table 2
Angiographical characteristics at baseline.
DES (n = 172) BMS  (n = 124) p-Value, DES
vs. BMS
Target coronary artery (%) 0.12




ACC/AHA lesion class B2/C (%) 65 51 <0.01
PCI to ISR (%) 16.4 6.2 <0.01
Angiographic measurement
Lesion length (mm) 20.6 ± 11.4 15.7 ± 9.8 <0.01
RVD  (mm)  2.5 ± 0.5 2.7 ± 0.6 <0.01
MLD (mm)  0.7 ± 0.5 0.8 ± 0.4 <0.01
%DS  (%) 75.6 ± 16.8 69.5 ± 13.5 <0.0118 M. Sugihara et al. / Journal 
ospital, and the analysis was performed using our database of
U-Registry (UMIN000005679). This study was approved by the
ndependent Review Board of Fukuoka University Hospital [10-1-
8 (09-105)]. The 1572 consecutive patients (1837 lesions) who
nderwent successful DES or BMS  implantation were registered
rom January 2003 to September 2009. In this study, we  selected
35 patients (698 lesions) who had a history of stable angina and
resented with at least 1 signiﬁcant stenotic lesion with >50% diam-
ter stenosis (%DS) and were implanted with a successful minimum
iameter of BMS  or DES (stent diameter = 2.5 mm).  Thus, a small
oronary artery lesion was deﬁned as a successful minimum stent
mplantation in this study. A lesion was deﬁned with one PCI lesion.
n addition, we randomly selected 124 BMS  and 172 DES lesions that
ad undergone complete data analysis and evaluation. The end-
oint of the procedure was thrombolysis in myocardial infarction,
ngiographic %DS < 30%, and no major dissection that would com-
romise the ﬂow of the vessel. TLR was performed if the lesion
ad signiﬁcant luminal stenosis (>50%DS) in the presence of angi-
al symptoms and/or proven myocardial ischemia in the target
essel.
The administration of antiplatelets (100 mg/day aspirin +
00 mg/day ticlopidine or 75 mg/day clopidogrel) was started in
ll patients prior to stent placement. For BMS  implantation, the
dministration of antiplatelets except aspirin was to be continued
or at least 2 weeks after PCI. On the other hand, the administration
f all antiplatelets was to be continued for at least 9 months after
ES implantation. Follow-up periods of BMS  and DES groups were
77 ± 257 days and 310 ± 359 days, respectively.
The cumulative incidence of major adverse cardiac events
MACE) was deﬁned as death, myocardial infarction (MI), or TLR,
ither percutaneous or surgical. The deﬁnition of MI  included ST-
 and non-ST-T elevation. For a diagnosis of MI,  the patient had
o have met  either of the following criteria: evident ischemic
lectrocardiogram changes or elevation of cardiac biomarker con-
entrations. We  used the deﬁnition of stent thrombosis as deﬁned
y the Academic Research Consortium criteria [7].  Almost all of
he blood samples were drawn after an overnight fast, since the
amples were essentially based on inpatient data.
uantitative coronary angiography
All angiograms were analyzed qualitatively and quantitatively
t the angiographic core laboratory at Fukuoka University Hos-
ital. Quantitative coronary angiography (QCA) was performed
or all qualifying angiograms using CMS  (MEDIS, Leiden, The
etherlands). Binary restenosis was deﬁned as >50% diameter
tenosis. QCA analysis included stent measurement; the minimal
umen diameter (MLD) was  conﬁned within the proximal and dis-
al stent borders. In-stent restenosis (ISR) at follow-up was deﬁned
s luminal narrowing of more than 50% occurring in the segment
ith the stent or within a 5 mm segment proximal or distal to the
tent.
tatistical analysis
Statistical analysis was performed using SAS software, version
.1 (SAS Institute, Cary, NC, USA) at Fukuoka University. The chi-
quare test was  used for intergroup comparisons of categorical
ariables. For intergroup comparisons of continuous variables, we
sed Wilcoxon’s rank-sum test and Student’s t-test. We  also used multiple logistic regression analysis for the multivariate analysis
o identify independent predictors of ISR. The values are expressed
s mean ± SD. Statistical signiﬁcance was deﬁned as a p-value less
han 0.05.iology 61 (2013) 117–121
Results
Patient and angiographical characteristics at baseline
Patient and angiographical characteristics at baseline are pre-
sented in Tables 1 and 2, respectively. Patient characteristics at
baseline were similar between the DES and BMS  groups except for
the percentage of dyslipidemia. Among the angiographical charac-
teristics at baseline, the percentage of type B2/C lesions in the DES
group was  signiﬁcantly greater than that in the BMS  group. The DES
group had more ISR lesions than the BMS  group. The DES group hadDES, drug-eluting stent; BMS, bare metal stent; LMT, left main trunk; LAD, left ante-
rior descending artery; LCX, left circumﬂex coronary artery; RCA, right coronary
artery; ACC/AHA, American College of Cardiology/American Heart Association; PCI,
percutaneous coronary intervention; ISR, in-stent restenosis; RVD, reference vessel
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rocedural results
We used more sirolimus-eluting stents (SES) than paclitaxel-
luting stents (PES) (SES 90% vs. PES 10%) for DES implantation.
he procedural results are shown in Table 3. Stent length in the
ES group was signiﬁcantly longer than that in the BMS  group, and
LD  in-stent or in-segment was signiﬁcantly smaller in the DES
roup. In addition, %DS in-stent or in-segment in the DES group
as signiﬁcantly higher than that in the BMS  group
ngiographical and clinical outcomes at follow-up
Angiographical and clinical outcomes are shown in Table 4. The
ES group had better QCA data (RVD, MLD, %DS and late loss) than
he BMS  group. In particular, the DES group showed greater reduc-
ions in late loss than the BMS  group.
MACE were similar between the groups. In particular, there was
o signiﬁcant difference in the TLR rate, whereas ISR in the DES
roup was signiﬁcantly lower than that in the BMS  group.
ultivariate predictors of in-stent restenosis
We  analyzed the factors associated with ISR in patients (Fig. 1a)
nd angiographical characteristics (Fig. 1b), separately, by a uni-
ariate or a multivariate analysis of ISR. In patient characteristics,
e selected independent variables (coronary risk factors in addi-
ion to prior PCI and DES use) for ISR. In a univariate analysis,
ender, DM, prior PCI, and DES use were associated with ISR.
able 3
rocedural results.
DES (n = 172) BMS  (n = 124) p-Value DES
vs. BMS
Treated lesions (n) 1.31 ± 0.47 1.23 ± 0.46 0.17
Stent length (mm)  26.2 ± 11.23 18.1 ± 9.18 <0.01
RVD  in stent (mm) 2.83 ± 0.48 3.03 ± 0.49 0.17
RVD in segment (mm)  2.65 ± 0.51 2.92 ± 0.58 0.15
MLD  in stent (mm) 2.42 ± 0.48 2.65 ± 0.48 <0.01
MLD  in segment (mm)  1.93 ± 0.49 2.19 ± 0.56 0.02
%DS in stent (%) 15.2 ± 9.42 11.9 ± 10.7 0.01
%DS in segment (%) 29.7 ± 14.7 25.1 ± 16.0 0.01
ES, drug-eluting stent; BMS, bare metal stent; RVD, reference vessel diameter;
LD, minimal lumen diameter; DS, diameter stenosis.
able 4
linical and angiographical outcomes at follow-up.
DES (n = 125) BMS  (n = 95) p-Value, DES
vs. BMS
MACE (%) 20 (16.1) 22 (23.1) 0.11
Death (%) 2 (1.6) 2 (2.1) 0.98
MI  (%) 4 (3.2) 2 (2.1) 0.45
TLR  (%) 19 (15.2) 16 (16.8) 0.16
Thrombosis (%) 1 (0.8) 1 (0.5) 0.31
ISR  (%) 24 (19.2) 27 (28.4) 0.01
DES (n = 162) BMS  (n = 114) p-Value, DES
vs. BMS
RVD in stent (mm)  2.85 ± 0.44 2.75 ± 0.57 <0.01
RVD in segment (mm) 2.88 ± 0.42 2.53 ± 0.57 <0.01
MLD  in stent (mm)  2.25 ± 0.66 1.88 ± 0.70 <0.01
MLD  in segment (mm)  1.90 ± 0.73 1.76 ± 0.69 0.01
%DS in stent (%) 20.8 ± 18.8 32.7 ± 19.2 <0.01
%DS in segment (%) 33.3 ± 18.9 40.5 ± 18.4 0.05
Late loss (mm) 0.13 ± 0.63 0.77 ± 0.62 0.01
ES, drug-eluting stent; BMS, bare metal stent; MACE, major adverse cardiac event;
I,  myocardial infarction; TLR, target lesion revascularization; ISR, in-stent resteno-
is; RVD, reference vessel diameter; MLD, minimal lumen diameter; DS, diameter
tenosis.iology 61 (2013) 117–121 119
Next, we  performed a multivariate analysis for ISR using these
factors. DM [odds ratio (OR), 1.637; 95% conﬁdence interval
(CI) 1.232–2.183; p = 0.0007] and prior PCI (OR, 1.484; 95% CI
1.119–1.973; p = 0.0063) were identiﬁed as independent predictors
of ISR (Fig. 1a). Moreover, we selected signiﬁcant variables in angio-
graphical characteristics by a multivariate analysis. RVD pre, stent
length, and DES use were also identiﬁed as independent predictors
of ISR (Fig. 1b).
Discussion
In this study, DES implantation was associated with a superior
clinical outcome of ISR compared to BMS  implantation. It is well
known that DES shows a lower incidence of late loss than BMS  [8].
Our data also indicated that there were signiﬁcant differences in
late loss, MLD, and %DS between the DES and BMS  groups. DES
use was an independent predictor of ISR, although the DES group
included more severely diseased small coronary arteries.
The incidences of death and MI  in the DES group were simi-
lar to those in the BMS  group. A previous study identiﬁed smaller
RVD as a predictor of stent thrombosis [9].  The e-CYPHER registry
reported that the rates of stent thrombosis in smaller vessels and
MI  were higher than those in larger vessels in the DES and BMS
groups [10,11]. In addition, Ishigami et al. reported that small-
diameter (2.5 mm)  stents, the tissue characteristics of the stented
coronary segment, and DM were important predictors of a higher
rate of uncovered struts [12]. One possible explanation for this
result is that the present study had a short follow-up period. If
we had used a longer follow-up period, there might be differences
in these clinical outcomes. In fact, the use of SES in the percuta-
neous revascularization of small coronary arteries was associated
with improvements in major adverse cardiac and cerebrovascu-
lar events, which included death, non-fatal myocardial infarction,
ischemia-driven TLR, and cerebrovascular accident, after 2 years of
follow-up in comparison with BMS  [13].
The incidence of TLR in the DES group in our study was higher
than that in a previous study [14]. One possible explanation for
this difference is that our study included more severe lesions
with regard to MLD  and lesion length than other trials. For exam-
ple, a subgroup analysis in the SIRTAX (Sirolimus-Eluting Stent
Compared With Paclitaxel-Eluting Stent for Coronary Revasculari-
zation) trial showed that MLD  and lesion length were 2.5 ± 0.2 mm
and 11.7 ± 6.4 mm,  respectively [15]. The DES  group in our study
tended to show a higher prevalence of DM than the BMS  group.
Generally, patients with DM have more diffuse and smaller-vessel
disease, and their lesion background may  be more severe. In fact,
DM and RVD (pre) were predictors of ISR in our study.
In this study, MLD, %DS, and late loss were similar to those in
other randomized controlled trials [14]. In addition, there was  no
signiﬁcant difference in the incidence of TLR between the DES and
BMS  groups, whereas ISR in the DES group was  signiﬁcantly lower
than that in the BMS  group. This discrepancy may  have been due
to differences in the historical background of the stent.
Of the two types of DES used in this study, we used more SES
(90%) than PES (10%) for DES implantation. This may  be because
ISAR-SMART (intracoronary stenting or angioplasty for restenosis
reduction in small arteries) showed signiﬁcantly less angiographic
restenosis and a lower incidence of TLR with the use of SES than
with PES [15]. SES is more effective for suppressing neointimal
proliferation, which results in a lower incidence of anigographic
restenosis and a reduced need for TLR. The SIRTAX trial reported
that SES reduced MACE by 55%, mainly driven by a 69% reduction
in the incidence of TLR [16]. These reports may  have led to the
greater use of SES than of PES in our study. Four types of DES are
currently available for clinical use in Japan. Although lower late






Gender 1.643(1.176-2.328) 0.0043 1.413 (0.963-2.072) 0.0768
Age 0.997(0.983-1.011) 0.6475
DM 1.540(1.169-2.037) 0.0023 1.637 (1.232-2.183) 0.0007
DL 0.756(0.562-1.016) 0.0640
HT 0.956(0.685-1.333) 0.7888
Prior PCI 1.548(1.178-2.040) 0.0018 1.484 (1.119-1.973) 0.0063
Smoking 1.060(0.791-1.417) 0.6935
DES use 0.918(0.891 - 0.944) <0.0001 0.919 (0.887-0.951) <0.0001
RVD pre 0.490(0.340-0.696) 0.0002 0.560 (0.380-0.816) 0.0029
MLD pre 0.568(0.373-0.859) 0.0078 0.798 (0.251-3.112) 0.7197
%DS pre 1.004(0.994-1.015) 0.4466
RVD final 0.675(0.493-0.924) 0.0141 1.339 (0.468-3.698) 0.5819
MLD final 0.552(0.400-0.756) 0.0003 0.823 (0.212-3.066) 0.7720 
%DS final 1.014(1.003-1.026) 0.0159 1.007 (0.971-1.038) 0.6917 
Stent length 1.026(1.008-1.044) 0.0043 1.025 (1.008-1.043) 0.0036 
DES use 0.921(0.896-0.946) <0.0001 0.927 (0.887-0.968) 0.0007
OR, odds ratio; CI, confidence interval; DM, diabetes mellitus; HT, hypertension; DL, dyslipidemia; PCI, percutaneous coronary
intervention; DES, drug-eluting stent; RVD, reference vessel diameter; MLD, minimal lumen diameter; DS, diameter stenosis.
1.0
a. Patients’  characteristics
b. Angiographical characteristics



















[cal  characteristics (b), separately. OR, odds ratio; CI, conﬁdence interval; DM, diabet
VD,  reference vessel diameter; MLD, minimal lumen diameter; DS, diameter steno
oss is an important element for the reduction of TLR, especially
n small coronary arteries, uncovered stent struts are the primary
ause of late stent thrombosis. The healing process of neointima is
ot the same among different types of DES [17]. Thus, we should
elect and use DES based on the particular lesion characteristics to
chieve better long-term clinical results.
tudy limitations
This was a retrospective study. The relatively small sample size
as further limitation. In addition, we used both SES and PES as
ES. A longer study period will be needed to determine whether
here are differences in cardiovascular events between the groups.
onclusions
MACE in DES implantation is similar to that in BMS  implantation,
ven though DES were implanted in more severe small coronary
rteries. Our results reveal that DES implantation in small coronary
rteries is more effective than BMS  implantation for reducing ISR.
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